Clinical trials
Metastatic Hepatocellular Carcinoma clinical trials
Below are recruiting metastatic hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 150 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03949231RecruitingPhase 3
Infusion immunotherapy through the liver artery for liver cancer
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
Guanzhou, GuangdongAges 18–80 - NCT05323201RecruitingPhase 1/Phase 2
B7H3 CAR-T therapy for advanced liver cancer
This trial tests an immune therapy made from your own blood cells (CAR-T) to treat advanced, unresectable liver cancer. It’s designed for people whose tumor has a specific marker called B7H3 and who meet blood, organ, and safety requirements.
Xuzhou, JiangsuAges 18–70 - NCT05377034RecruitingPhase 2
Y-90 and immunotherapy vs Y-90 plus placebo for liver cancer
This phase 2 study tests whether adding immunotherapy drugs (atezolizumab and bevacizumab) after Y-90 treatment works better and is safe compared with Y-90 followed by placebo. It is for people with liver cancer that has not spread outside the liver but is difficult to treat.
BeijingAges 21–99 - NCT05407519RecruitingPhase 2
Tislelizumab and sitravatinib after liver cancer surgery to prevent relapse
This trial studies whether combining two medicines (tislelizumab and sitravatinib) given after curative liver cancer surgery can help prevent the cancer from coming back. It is for people with liver cancer at high risk of recurrence, who have fully recovered from surgery and have no spread beyond the liver.
Hefei, AnhuiAges 18–70 - NCT05476432RecruitingPhase 3
One-day versus two-day chemotherapy for unresectable liver cancer
This study compares two schedules of chemotherapy to treat liver cancer that cannot be removed with surgery. It aims to see whether the shorter schedule works about as well, with similar safety.
Foshan, GuangdongAges 18–75 - NCT05482516RecruitingPhase 3
Testing blood test–guided treatment for GI cancers in remission
This Phase 3 study tests whether giving treatment based on a positive blood test for “minimal cancer signals” (ctDNA) can help people with certain GI cancers stay cancer-free longer. It focuses on people who have finished curative-intent therapy and currently have no visible disease on scans, but their blood test is still positive.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05652920RecruitingPhase 1/Phase 2
CAR T-cell therapy for liver cancer that has GPC3
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–70 - NCT05718492Recruiting
Tested HAIC for liver cancer after prior immunotherapy
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
Guangzhou, GuangdongAges 18–75 - NCT05992584RecruitingPhase 2
Lenvatinib, sintilimab, and SIRT for liver cancer
This trial tests a combination of two drugs (lenvatinib and sintilimab) plus a procedure called SIRT (radioactive beads) for people with liver cancer that can't be surgically removed. The goal is to see if this triple approach works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06077591Recruiting
Genetic and organoid testing to guide cancer treatment
This trial uses advanced testing (genetic sequencing and lab-grown tumor models) to find the best treatment for people with advanced solid tumors that haven't responded to at least one standard treatment. The goal is to personalize therapy based on your tumor's unique features.
Hong Kong, N.T.Ages 18–100 - NCT06294548RecruitingPhase 1/Phase 2
Valemetostat plus atezolizumab and bevacizumab for advanced liver cancer
This trial tests a combination of three drugs—valemetostat, atezolizumab, and bevacizumab—for people with advanced liver cancer (HCC) who have not had systemic treatment before. The goal is to see if this combination can shrink tumors or slow disease progression.
Birmingham, AlabamaAges 18 years+ - NCT06397222RecruitingPhase 2
Combination therapy for advanced liver cancer
This trial tests a combination of three treatments: an immunotherapy drug (Sintilimab), a targeted therapy (Bevacizumab), and a type of internal radiation (SIRT) for people with intermediate or advanced liver cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06883539RecruitingPhase 1
Study of LXP1788 for advanced solid tumors
This trial tests a new drug called LXP1788 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how it affects the body.
TaichungAges 18 years+ - NCT06914648Recruiting
Liver preparation before surgery study for certain liver cancers
This study tests a procedure called portal vein embolization (PVE) to help grow the healthy part of the liver before surgery. It may be an option for people with certain liver cancers who need more healthy liver tissue before their operation.
New Haven, ConnecticutAges 18 years+ - NCT06940102Recruiting
A study on megestrol acetate for weight loss in advanced digestive cancer
This study tests a special form of megestrol acetate (a medicine that can help with appetite and weight gain) in people with advanced digestive system cancers who are about to start or are already taking a type of targeted therapy called a TKI. The goal is to see if it helps with cancer-related weight loss and wasting (cachexia).
Shenyang, LiaoningAges 18 years+ - NCT07053072RecruitingPhase 1
PD-1 mRNA vaccine for advanced liver cancer
This trial tests a new mRNA vaccine for people with advanced liver cancer that has returned or spread after other treatments. The vaccine aims to help your immune system fight the cancer more effectively.
Chengdu, SichuanAges 18–70 - NCT07062055RecruitingPhase 2
A study of combination therapy for advanced liver cancer with spread
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
Jinan, ShandongAges 18–70 - NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT07192185RecruitingPhase 2
Chemo plus immunotherapy for advanced liver cancer after first treatment fails
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
Guangzhou, GuangdongAges 18–75 - NCT07197554RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
Duarte, CaliforniaAges 16 years+ - NCT07284121Recruiting
Patient satisfaction and safety of Atezolizumab in routine care
This study tracks how well Atezolizumab (Tecentriq) works for people with certain lung or liver cancers in everyday medical practice. It helps doctors understand if patients are satisfied with their treatment and how it affects their quality of life.
KremsAges 18 years+ - NCT07365930Recruiting
TIPS treatment support for liver cancer patients on Atezo + Bev
This study looks at whether adding TIPS (a procedure to reduce fluid buildup) to standard immunotherapy (atezolizumab and bevacizumab) helps people with advanced liver cancer who also have cirrhosis. It's for patients whose cancer cannot be removed by surgery or has progressed after other local treatments.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT07376707RecruitingPhase 1
Study of TGI-5 alone or with nivolumab for advanced solid tumors
This trial tests a new drug called TGI-5, either by itself or combined with another drug (nivolumab), for people with advanced cancer that hasn't responded to standard treatments. It's looking for patients with certain types of solid tumors, especially colorectal, melanoma, lung, or others that have stopped responding to therapy.
ShanghaiAges 18 years+ - NCT07422753RecruitingPhase 2
TACE with immunotherapy drugs for advanced liver cancer
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
Hangzhou, ZhejiangAges 18–75
Hear when a new Metastatic Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic hepatocellular carcinoma?
- Yes. Clin2 currently lists 150 recruiting metastatic hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.